Substituted Dimeric Quinazoline Derivative, Its Preparation And Its Use In Pharmaceutical Compositions For The Treatment Of Type I And Ii Diabetes

Patent No. EP3517539 (titled "Substituted Dimeric Quinazoline Derivative, Its Preparation And Its Use In Pharmaceutical Compositions For The Treatment Of Type I And Ii Diabetes") was filed by Boehringer Ingelheim on Jul 13, 2012. The application was issued on Dec 14, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
HAMM & WITTKOPPSep 14, 2023HAMM & WITTKOPP
KNPP PARTGMBBSep 14, 2023DR VOLGER
KNPP PARTGMBBSep 14, 2023VOLGER
MAIWALDSep 13, 2023MAIWALD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3517539

BOEHRINGER INGELHEIM
Application Number
EP19151416A
Filing Date
Jul 13, 2012
Status
Granted And Under Opposition
Nov 11, 2022
Publication Date
Dec 14, 2022